Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $350K | $652K | $3.50M |
| Revenue growth | — | 86.3% | 436.5% |
| Operating income | -$51.9M | -$53.1M | -$52.6M |
| Operating margin | -14822.6% | -8142.3% | -1502.4% |
| Net income | -$49.3M | -$51.8M | -$80.4M |
| Net margin | -14083.1% | -7943.4% | -2298.5% |
| EPS (diluted) | -$124.80 | -$11.04 | -$2.65 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$44.2M | -$45.6M | -$29.6M |
| Capital expenditures | $678K | $441K | $279K |
| Free cash flow | -$44.8M | -$46.0M | -$29.8M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $38.4M | $64.0M | $110M |
| Total assets | $54.9M | $78.3M | $118M |
| Total liabilities | $16.5M | $15.2M | $70.1M |
| Shareholders' equity | -$124M | $63.1M | $47.7M |
| Retained earnings | -$160M | -$212M | -$292M |
| Shares (wtd avg diluted) | 395K | 4.69M | 30.4M |
Every figure is extracted from Camp4 Therapeutics Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.